Stay updated on Dociparstat for Severe COVID-19 High-Risk Adults Clinical Trial
Sign up to get notified when there's something new on the Dociparstat for Severe COVID-19 High-Risk Adults Clinical Trial page.

Latest updates to the Dociparstat for Severe COVID-19 High-Risk Adults Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.6%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has undergone significant revisions, including updates to the study design and randomization details for the dociparstat sodium trial related to COVID-19. The revision number has also been updated from v2.14.4 to v2.15.0.SummaryDifference32%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.6%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check59 days agoChange DetectedDifference0.5%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
Stay in the know with updates to Dociparstat for Severe COVID-19 High-Risk Adults Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dociparstat for Severe COVID-19 High-Risk Adults Clinical Trial page.